Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oral Expectorant Market
Oral Expectorant Market Trends
- Report ID: GMI8788
- Published Date: Apr 2024
- Report Format: PDF
Oral Expectorant Market Trends
- The burgeoning geriatric demographic is significantly driving the market expansion. With increasing age, they become more susceptible to respiratory conditions such as bronchitis, pneumonia, and asthma due to factors like a weakened immune system, diminished lung function, and underlying health concerns. Therefore, with a larger proportion of the population entering older age brackets globally, there is a consequent increase in the prevalence of respiratory ailments among this demographic.
Frequently Asked Questions (FAQ) :
The global oral expectorant industry crossed USD 4.2 billion in 2023 and is expected to reach USD 5.7 billion by 2032, due to the increasing prevalence of respiratory diseases worldwide.
The secretion enhancer drug type segment held a decent share of the market in 2023 and is expected to grow at 3.7% CAGR between 2024 – 2032, driven by ongoing R&D in respiratory medicine.
North America oral expectorant market held a major share in 2023 and is anticipated to grow at 3.2% CAGR till 2032, due to its growing patient population and rising respiratory diseases.
Abbott Laboratories, AstraZeneca, Cipla Inc., Genexa Inc., GlaxoSmithKline (GSK) plc, Merck KGaA, Perrigo Company plc, Reckitt Benckiser Group PLC among others
Oral Expectorant Market Scope
×
Get a free sample of
Oral Expectorant Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below